RecruitingPhase 1NCT07239609

ACT for Individuals With MNCD and Their Care Partners

Acceptance and Commitment Therapy for Individuals With MNCD and Their Care Partners: An In-Person and Telehealth Individual Therapy Approach


Sponsor

Texas Tech University

Enrollment

100 participants

Start Date

Apr 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

This project aims to implement and evaluate a dyadic intervention (i.e., acceptance commitment therapy) for persons with AD/ADRD and their care partners. We hypothesize the intervention will be feasible, acceptable, and show preliminary efficacy of the dyadic interveniotns.


Eligibility

Min Age: 18 Years

Inclusion Criteria10

  • Inclusion (person with MCI or MNCD):
  • +
  • MMSE= 21-27
  • Able to communicate in English
  • Inclusion (care partner):
  • +
  • Identifies as a care partner of a person with MNCD
  • Able to communicate in English
  • MMSE= 28-30
  • Is a family member or friend of the person with MNCD

Exclusion Criteria6

  • Exclusion (person with MCI or MNCD):
  • Currently in an intervention for reducing anxiety or depression related to their dementia
  • MMSE= 28+ or less than 21
  • Exclusion (care partner):
  • MMSE= <28
  • Is a formal (paid) caregiver

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALAcceptance Commitment Therapy

Acceptance and Commitment Therapy (ACT) is a form of cognitive-behavioral therapy that aims to enhance psychological flexibility through six core processes: acceptance, cognitive defusion, being present, self-as-context, values clarification, and committed action. Rather than attempting to eliminate difficult thoughts and feelings, ACT encourages individuals to accept them while committing to behavior changes consistent with their personal values.


Locations(1)

Texas Tech University Plaza Building

Lubbock, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07239609


Related Trials